ВЫБОР ГЕПАРИНА ДЛЯ АНТИТРОМБОТИЧЕСКОЙ МОДИФИКАЦИИ СОСУДИСТЫХ БИОПРОТЕЗОВ

Purpose. Extra treatment of biomaterial with heparin is a promising method of artery xenograft hemocompatibility increase. The study was aimed at experimentally assessing quantitative parameters of unfractionated and low molecular weight heparins immobilization on the biomaterial and their impact on graft hemocompatibility. Materials and methods. Xenoarteries treated with ethylene glycol diglycidyl ether were used. Unfractionated heparin (UFH) by NPO «Synthez» (Russia) and low molecular weight heparin (LMWH) – enoxaparin sodium by «Clexane» (France) were used to treat the biomaterial. The amount of immobilized heparins was assessed using three independent methods. The impact of heparin on biomaterial hemocompatibility was assessed in vitro. Results. The amount of immobilized enoxaparin was significantly lower than that of UFH. However, this amount of LMWH was enough for having a smoothing effect on xenogafts surface and decreasing platelet aggregation by 24 %. Biomaterial treatment with both UFH and LMWH signifi cantly decreased blood protein adsorption. Conclusion. Based on the obtained data we can suggest that enoxaparin sodium has a greater potential for antithrombotic modification of epoxy-treated arterial grafts.